Bonner T I
National Institute of Mental Health, Bethesda, MD, USA.
Br J Pharmacol. 2014 Mar;171(5):1231-40. doi: 10.1111/bph.12526.
Alternative splicing of mRNAs occurs in the majority of human genes, and most differential splicing results in different protein isoforms with possibly different functional properties. However, there are many reported splicing variations that may be quite rare, and not all combinatorially possible variants of a given gene are expressed at significant levels. Genes of interest to pharmacologists are frequently expressed at such low levels that they are not adequately represented in genome-wide studies of transcription. In single-gene studies, data are commonly available on the relative abundance and functional significance of individual alternatively spliced exons, but there are rarely data that quantitate the relative abundance of full-length transcripts and define which combinations of exons are significant. A number of criteria for judging the significance of splice variants and suggestions for their nomenclature are discussed.
大多数人类基因中都会发生mRNA的可变剪接,并且大多数差异剪接会产生可能具有不同功能特性的不同蛋白质异构体。然而,有许多报道的剪接变异可能相当罕见,而且给定基因的所有组合可能的变体并非都以显著水平表达。药理学家感兴趣的基因通常表达水平很低,以至于在全基因组转录研究中没有得到充分体现。在单基因研究中,通常可获得关于单个可变剪接外显子的相对丰度和功能意义的数据,但很少有数据能定量全长转录本的相对丰度并确定哪些外显子组合是有意义的。本文讨论了一些判断剪接变体重要性的标准及其命名建议。